TargetBeta
HTT
huntingtin · also IT15, HD · Receptor ligands
3 programs in company-led studies act on HTT, from 3 companies: 3 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| votoplam | Novartis | phase 3 | 32 running | – | the company's pipeline |
| SKY-0515rule | Skyhawk Therapeutics | phase 3 | 22 running | – | the studies' text |
| L-(+)-methylenetetrahydrofolic acidrule | Isofol Medical AB | phase 3 | 51 running | – | NCIt |
Conditions their studies are in
- Huntington Disease, 2 programs
- Colonic Neoplasms, 1 program
- Colorectal Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- May 2027SKY-0515 · Skyhawk Therapeutics · phase 3 · NCT06873334
- Nov 30, 2028L-(+)-methylenetetrahydrofolic acid · Isofol Medical AB · phase 3 · NCT06922383
- Jul 16, 2029votoplam · Novartis · phase 3 · NCT06254482
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.